Comparing 5-ALA Photodynamic Therapy and CO2 Laser Treatment for Persistent Low-Grade Cervical Lesions in Women with High-Risk HPV Infection

What this Trial Is About

Researchers are evaluating two different treatments for women who have had persistent low-grade cervical lesions caused by high-risk HPV infection for more than one year. The study compares 5-aminolevulinic acid 5-ALA photodynamic therapy with CO2 laser treatment to determine which approach may better reduce or eliminate these cervical lesions. This non-randomized controlled trial focuses on women aged 18 to 65 years with confirmed high-risk HPV-related lesions. Participants receive either 5-ALA photodynamic therapy, which involves applying a special cervical gel followed by 25 minutes of laser light exposure repeated three times, or CO2 laser therapy, which removes the cervical lesions in a single session by ablating tissue to a specific depth and width. Both treatments are designed to target persistent low-grade cervical lesions associated with high-risk HPV infection. During the study, women will be monitored for changes in their cervical lesions, with the main outcome measured six months after the last photodynamic therapy session or the CO2 laser treatment. Researchers will also check for any adverse effects six months following CO2 laser therapy. Participants will undergo examinations and follow-up visits as part of the treatment and assessment process, which continues until the study ends in June 2025.

Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection